# ADR 500 — Enterprise Biotechnology Mission, Vision & Strategic Scope (P217-A)

## Status

Accepted

## Context

P217 foundation (ADR 499) established SoR `biotechnology`. Before strategic architecture (P217-B), MEOS requires an immutable mission, vision, strategic purposes/objectives, bio capability framework, value streams, maturity model, governance strategy, and evolution roadmap.

## Decision

1. Extend SoR `biotechnology` with fabric `meos_bio_intelligence_strategic_framework` at `/api/v1/biotechnology/mission*`.
2. Codify mission/vision, five strategic purposes, seven objectives, six domains, four capability levels, four value streams, five maturity levels, five evolution phases.
3. Bind bio governance to Policy Engine + Workflow; privacy/security to Identity + Zero Trust; intelligence to P214-Z / P215-Z / P216-Z ACL.
4. Forbid sibling mission BCs; never replace P217 foundation, hospital, laboratory, pharmacy, or robotics.
5. Serve as strategic foundation for P217-B.

## Consequences

Positive: Clear strategic north star for biotechnology series.  
Negative: Strategy must stay synchronized as P217-B capabilities deepen.

## Alternatives rejected

- Sibling `bio_mission` BC outside SoR biotechnology.
- Embedding clinical strategy ownership inside hospital/laboratory SoRs.

## Related

Law: `ENTERPRISE_BIOTECHNOLOGY_MISSION.md`  
Prior: ADR 499 · Next: P217-B
